From: Crosstalk between autophagy and microbiota in cancer progression
Drugs | Cancer type | Clinical trial / Animal experiment | Phase | Ref. / Trial ID |
---|---|---|---|---|
Chloroquine | Small cell lung cancer | Clinical trial | Phase I | NCT00969306 |
 | Small cell lung cancer | Clinical trial | Phase I | NCT01575782 |
 | Breast cancer | Clinical trial | Phase II | NCT02333890 |
Hydroxychloroquine | Estrogen receptor-positive breast cancer | Clinical trial | Phase Ib/II | NCT02414776 |
 | Prostate carcinoma | Clinical trial | Phase I | NCT02421575 |
 | Solid tumors | Clinical trial | Phase I | NCT03015324 |
 | Melanoma | Clinical trial | Phase I | NCT00962845 |
 | Hepatocellular carcinoma | Clinical trial | Phase I/II | NCT02013778 |
 | B-CLL | Clinical trial | Phase II | NCT00771056 |
 | Renal cancer | Clinical trial | Phase Ib | NCT01144169 |
Sorafenib | Hepatocellular carcinoma | Clinical trial | Phase Ib/II | NCT03211416 |
Lys05 | Melanoma, colon cancer | Animal experiment | / | [136] |
DQ661 | Melanoma, pancreatic cancer, colorectal cancer | Animal experiment | / | |
SAR405, SB02024 | Melanoma, colorectal cancer | Animal experiment | / | [139] |
Mefloquine | Pancreatic ductal adenocarcinoma | Animal experiment | / | [140] |
Spautin-1 | Prostate cancer | Animal experiment | / | [141] |
 | Melanoma | Animal experiment | / | [142] |
Rapamycin | Bladder cancer | Clinical trial | Phase II | NCT04375813 |
 | Advanced cancers | Clinical trial | Phase Ib | NCT00707135 |
 | HNSCC | Animal experiment | / | [143] |
 | Lung squamous cell carcinoma | Animal experiment | / | [144] |
Temsirolimus | Prostate cancer | Clinical trial | Phase II | NCT00919035 |
 | Advanced cancers | Clinical trial | Phase I/II | NCT00877773 |
 | HNSCC | Clinical trial | Phase II | NCT01172769 |
 | Advanced bladder cancer | Clinical trial | Phase II | NCT01827943 |
 | Cervical cancer | Clinical trial | Phase II | NCT01026792 |
 | Metastatic neuroendocrine carcinoma | Clinical trial | Phase II | NCT00093782 |
 | Liver cancer | Clinical trial | Phase II | NCT01079767 |
 | Endometrial carcinoma | Clinical trial | Phase IIa | NCT02093598 |